Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 10/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | GLA | P06280 | 1/20 | 0.67 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.62 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.62 |
| ▸ | ST6GAL1 | P15907 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | MTOR | P42345 | 1/20 | 0.55 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.55 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.55 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citicoline SCHEMBL29356848 | 1.00 | P2RY2 (0.70) | P2RY2TSHRGLAP2RY6P2RY4 | |
| Citicoline SCHEMBL8303928 | 1.00 | P2RY2 (0.70) | P2RY2TSHRGLAP2RY6P2RY4 | |
| Citicoline SCHEMBL13933086 | 1.00 | P2RY2 (0.70) | P2RY2TSHRGLAP2RY6P2RY4 | |
| SCHEMBL23199844 | 0.94 | TSHR (0.64) | P2RY2TSHRGLAP2RY6P2RY4 | |
| Citicoline SCHEMBL50799 | 0.93 | TSHR (0.73) | P2RY2TSHRGLAP2RY6P2RY4 | |
| Citicoline SCHEMBL31413926 | 0.93 | TSHR (0.73) | P2RY2TSHRGLAP2RY6P2RY4 | |
| Citicoline SCHEMBL31554836 | 0.93 | TSHR (0.73) | P2RY2TSHRGLAP2RY6P2RY4 | |
| Citicoline SCHEMBL25411862 | 0.93 | TSHR (0.76) | P2RY2TSHRGLAP2RY6P2RY4 | |
| Citicoline SCHEMBL221081 | 0.93 | TSHR (0.73) | P2RY2TSHRGLAP2RY6P2RY4 | |
| Citicoline SCHEMBL4311534 | 0.93 | TSHR (0.76) | P2RY2TSHRGLAP2RY6P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4190319-A1 | PHARMACEUTICAL COMPOSITION COMPRISING MEMANTINE AND CITICOLINE | Novamedica Limited Liability Company (RU) | 2023-06-07 | — | — | EP | disclosed |
| US-20140099262-A1 | ISOTOPICALLY LABELED CDP-CHOLINE AND USES THEREOF | BRAIN WATCH LTD. (IL) | 2014-04-10 | — | — | US | disclosed |
| WO-2012164563-A1 | ISOTOPICALLY LABELED CDP-CHOLINE AND USES THEREOF | BRAIN WATCH LTD. (IL) | 2012-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140099262-A1 | ISOTOPICALLY LABELED CDP-CHOLINE AND USES THEREOF | CHAT, SLC5A7, CHKA | P2RY2 1191/4885TSHR 3585/4885GLA 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.